Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Suspended No phase listed Observational

Efficacy of Novel Drug-combinations for Relief of Psoriasis

ClinicalTrials.gov ID: NCT02394301

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02394301. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy of Novel Drug-combinations for Relief of Psoriasis (ENDURE)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

ENDURE is a prospective, observational study aimed to document clinical response and side effects associated with compounded psoriasis medications when prescribed as routine care. As a secondary initiative, this study will assess methotrexate systemic absorption and toxicity in patients prescribed a methotrexate-containing compounded formulation.

Study identification

NCT ID
NCT02394301
Recruitment status
Suspended
Study type
Observational
Phase
Not listed
Lead sponsor
Medimix Specialty Pharmacy, LLC
Industry
Enrollment
200 participants

Conditions and interventions

Conditions

Interventions

Not listed

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 2015 (Type not available)
Primary completion
Dec 2015 (Estimated)
Completion
Dec 2015 (Estimated)
Last update posted
May 18, 2015

2015

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
The Medimix Specialty Pharmacy, LLC Jacksonville Florida 32216 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02394301, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 18, 2015 · Synced Nov 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.